Magdalena Biosciences, a Joint Venture Between Jaguar Health and Filament Health, to Present October 16 at BIO Investor Forum
- by Raleigh News & Observer
- Oct 10, 2024
- 0 Comments
- 0 Likes Flag 0 Of 5
Magdalena aiming to submit Investigational New Drug (IND) application in early 2025 to the FDA for a next-generation psychoactive prescription drug candidate for potential mental health indications such as ADHD and schizophrenia,
Please first to comment
Related Post
Stay Connected
Tweets by elonmuskTo get the latest tweets please make sure you are logged in on X on this browser.
Sponsored
Popular Post
Tesla: Buy This Dip, Energy Growth And Margin Recovery Are Vastly Underappreciated
28 ViewsJul 29 ,2024